Pharmaceutical manufacturer Eli Lilly said Tuesday that it will limit the out-of-pocket cost of insulin to $35 per month to offset financial hardships due to the coronavirus pandemic.
The co-pay cap will cover the majority of the companys insulin, including ⦠[+1876 chars]Source
